266 related articles for article (PubMed ID: 20819491)
21. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
22. Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients.
Li W; Huang L; Guo H; Wei X; Liang Z
J Clin Virol; 2014 Oct; 61(2):199-203. PubMed ID: 25128391
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.
Wu Y; Chen Y; Zhu P; Ye B; Lu Y; Shi J; Tan Y; Zhao Y; Yu J; Lai X; Lan J; Si T; Ni L; Huang H; Luo Y
Ann Hematol; 2022 Mar; 101(3):631-641. PubMed ID: 34981143
[TBL] [Abstract][Full Text] [Related]
26. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study.
Wu XY; Li X; Chen ZH; Wen JY; Lin Q; Xing YF; Dong M; Wei L; Wang TT; Chen J; Lin ZX; Wan XB; Ruan DY; Ma XK
Tumour Biol; 2013 Apr; 34(2):909-18. PubMed ID: 23269606
[TBL] [Abstract][Full Text] [Related]
27. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
[TBL] [Abstract][Full Text] [Related]
28. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.
Yu S; Luo H; Pan M; Luis AP; Xiong Z; Shuai P; Zhang Z
Int J Clin Pharm; 2016 Oct; 38(5):1035-43. PubMed ID: 27450506
[TBL] [Abstract][Full Text] [Related]
29. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine.
Yeo W; Hui EP; Chan AT; Ho WM; Lam KC; Chan PK; Mok TS; Lee JJ; Mo FK; Johnson PJ
Am J Clin Oncol; 2005 Aug; 28(4):379-84. PubMed ID: 16062080
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.
Wang YH; Fan L; Wang L; Zhang R; Xu J; Fang C; Li JY; Xu W
Support Care Cancer; 2013 May; 21(5):1265-71. PubMed ID: 23151650
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy.
Yang Y; Du Y; Luo WX; Li C; Chen Y; Cheng K; Ding J; Zhou Y; Ge J; Yang X; Liu JY
Cancer Chemother Pharmacol; 2015 Apr; 75(4):783-90. PubMed ID: 25687988
[TBL] [Abstract][Full Text] [Related]
33. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Rossi G; Pelizzari A; Motta M; Puoti M
Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
[TBL] [Abstract][Full Text] [Related]
34. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
[TBL] [Abstract][Full Text] [Related]
35. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
37. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
[TBL] [Abstract][Full Text] [Related]
40. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
